scPharmaceuticals, which is commercializing injectable version of an intravenous drug for heart failure, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The Burlington, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol SCPH. scPharmaceuticals filed confidentially on August 31, 2017. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
